A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522867-13-00

Enrollment

Registered

2026-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

ORR per Investigator assessment using RECIST 1.1

Detailed description

DoR per Investigator assessment using RECIST 1.1 • DCR per Investigator assessment using RECIST 1.1 • CBR per Investigator assessment using RECIST 1.1 • PFS per Investigator assessment using RECIST 1.1 • OS, • AEs • Clinical laboratory data, Integrated analysis using population PK model approach, Please refer to Protocol for further secondary end points

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
ORR per Investigator assessment using RECIST 1.1	—

Secondary

Measure	Time frame
DoR per Investigator assessment using RECIST 1.1 • DCR per Investigator assessment using RECIST 1.1 • CBR per Investigator assessment using RECIST 1.1 • PFS per Investigator assessment using RECIST 1.1 • OS, • AEs • Clinical laboratory data, Integrated analysis using population PK model approach, Please refer to Protocol for further secondary end points	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 10, 2026